Cashu FinanceCashu Finance
  • Terminal
  • Pulse
  • Spotlight
  • News
  • Cashu Research
Log inSign Up
← Back to Terminal
  1. Stocks
  2. Basic Materials
  3. OTC
  4. NVZMY

Market Cap: $30.77B

NA

Novozymes A/S

NVZMY
OTC (Other OTC)USD
Invest in NVZMY
OverviewNewsAnalyst ReportsFinancialsPolitician TradesInsider TradesExecutive
Cashu FinanceCashu Finance

By Cashu Finance. Providing market news, analysis, and research for investors worldwide.

Company

StocksScreenersAboutAuthorsAdvertisersBrokersConferencesContact

Legal

Terms of ServicePrivacy PolicyEditorial PolicyCorrections Policy

© 2026 Cashu Technologies Pty Ltd. All rights reserved. Cashu Finance is a trademark of Cashu Technologies Pty Ltd.

The content published on Cashu Finance is for informational purposes only and should not be construed as investment advice, a recommendation, or an offer to buy or sell any securities. All opinions expressed are those of the authors and do not reflect the official position of Cashu Technologies Pty Ltd or its affiliates. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Cashu Finance and its contributors may hold positions in securities mentioned in published content. Any such holdings will be disclosed at the time of publication. Market data is provided on an "as-is" basis and may be delayed. Cashu Technologies Pty Ltd does not guarantee the accuracy, completeness, or timeliness of any information presented.

Cashu Research is part of Cashu Technology Pty Ltd, which is an authorised representative (AR # 001318029) of Adviser Solutions Group Pty Ltd (ABN 88 601 875 521) (AFSL 485946) (ASG).

This material is general advice only and is not an offer for the purchase or sale of any financial product or service. The material is not intended to provide you with personal financial or tax advice and does not take into account your personal objectives, financial situation or needs. Although we believe that the material is correct, no warranty of accuracy, reliability or completeness is given, except for liability under statute which cannot be excluded. Please note that past performance may not be indicative of future performance and that no guarantee of performance, the return of capital or a particular rate of return is given by Cashu Technologies Pty Ltd, any of their related body corporates or any other person. To the maximum extent possible, Cashu Technologies Pty Ltd, their related body corporates or any other person do not accept any liability for any statement in this material.

–
–(–)

Open

$63.62

Prev. Close

$66.20

High

$63.76

Low

$62.61

Key Statistics

52-Week Range64% of range
Low $49.90High $75.27
Market Cap
$30.77B
P/E Ratio
40.92x
EPS (TTM)
$1.45

More on Novozymes A/S

  • News & announcements
  • Financials

Novozymes A/S at a Glance

  • Highly profitable: keeps 15.6% of revenue as net profit.
Revenue (TTM)
$4.39B
Dividend Yield
1.44%
Price / Book
2.57x
Beta
0.62
Avg. Volume
28.49K

Company Profile

Established in 1925 and based in Bagsvaerd, Denmark, Novozymes A/S is a global provider of biological solutions, specializing in the development and sale of industrial enzymes, microorganisms, and probiotics. The company's reach extends internationally, serving markets in Denmark, the rest of Europe, North America, Asia Pacific, the Middle East, Africa, and Latin America. Novozymes' diverse portfolio includes protein solutions for the food and beverage sector, alongside a comprehensive suite of cleaning and hygiene offerings for industrial, medical, and household applications, such as drain openers, septic tank treatments, ware washing, and professional laundry. In agriculture, they supply solutions for various crops like corn, cotton, soybeans, and wheat, focusing on bioyield and biocontrol, in addition to animal health and nutrition products and aquaculture systems for warm water species. The company actively supports sustainable industrial processes with contributions to bioenergy (including ethanol, biodiesel, renewable diesel, biogas, and wastewater treatment), biorefining (encompassing fiber modification, bleach boosting, deposit control, starch modification, carbon capture), and applications for textiles and leather. Their extensive range of enzyme solutions, such as lipases, proteases, oxidoreductases, and carbohydrases, are crucial for processes like corn and wheat separation, liquefaction, and saccharification. Furthermore, Novozymes addresses human health with solutions targeting brain, oral, protective, immune, and gastrointestinal well-being, while also engaging in areas like biocatalysis, cell culture, and diagnostics.

CEOEster Baiget
SectorBasic Materials
IndustryChemicals - Specialty
Employees11.6K
IPO DateJan 20, 2010
ExchangeOTC
Exchange NameOther OTC
CurrencyUSD
Headquarters & Contact
AddressBiologiens Vej 2
City / State / ZIPLyngby, ND, 2800
CountryDenmark
Phone

NVZMY Stock FAQ

What does Novozymes A/S do?

Established in 1925 and based in Bagsvaerd, Denmark, Novozymes A/S is a global provider of biological solutions, specializing in the development and sale of industrial enzymes, microorganisms, and probiotics. The company's reach extends internationally, serving markets in Denmark, the rest of Europe, North America, Asia Pacific, the Middle East, Africa, and Latin America.

Where is Novozymes A/S stock listed?

Novozymes A/S trades on the Other OTC under the ticker NVZMY, priced in USD.

What is Novozymes A/S's market cap?

Novozymes A/S has a market capitalisation of $30.77B, based on its latest share price.

What is the P/E ratio of NVZMY?

NVZMY trades at 40.92 times its trailing 12-month earnings.

What is NVZMY's 52-week high and low?

Over the past 52 weeks NVZMY has traded between $49.90 and $75.27.

Does Novozymes A/S pay a dividend?

Yes. Novozymes A/S's dividend yields 1.44% at the current share price, paying out 61% of its earnings.

Is Novozymes A/S profitable?

Highly profitable: keeps 15.6% of revenue as net profit.

What do analysts think of NVZMY stock?

The analyst consensus rating for NVZMY is Hold.

Who is the CEO of Novozymes A/S?

Ester Baiget is the CEO of Novozymes A/S, which is headquartered in Lyngby.

Shares trade 3063% above a discounted cash flow (DCF) estimate of $2.09.
  • Low debt: borrowings are 28% of shareholders' equity.
  • Comfortable liquidity: 1.5x more short-term assets than short-term liabilities.
  • Analyst consensus rating: Hold.
  • Pays a dividend yielding 1.44%, paying out 61% of earnings.
  • Generated automatically from reported financial data. General information only, not financial advice.

    Fundamentals Scorecard

    Each pillar is scored out of 5 from the latest reported data.

    • Valuation

      Weak · 1.0/5

      Price vs earnings, book value and discounted cash flow.

    • Profitability

      Weak · 1.0/5

      Return on equity and return on assets.

    • Financial Health

      Strong · 4.0/5

      Debt levels and Altman Z-Score bankruptcy risk.

    • Fundamental Trend

      Fair · 2.8/5

      Piotroski F-Score: 9 checks on profit, leverage and efficiency.

    See the full financial breakdown →
    45 44 46 00 00
    Websitehttps://www.novonesis.com